Immune-based mechanisms of cytotoxic chemotherapy: Implications for the design of novel and rationale-based combined treatments against cancer

Cell Death and Differentiation

Volumn 21, Issue 1, 2014, Pages 15-25

  Bracci, L ^a   Schiavoni, G ^a   Sistigu, A ^a   Belardelli, F ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

cancer; cellular immunity; chemotherapy; combined therapies; immune system

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CANCER VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PEPTIDE VACCINE; PHOSPHATE; PLATINUM; TEMOZOLOMIDE; VINBLASTINE; VINCRISTINE;

ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; B LYMPHOCYTE; BLOOD SAMPLING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COLON CANCER; CROSS PRESENTATION; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG EFFECT; DRUG MEGADOSE; DRUG SENSITIVITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FIBROSARCOMA; HEMATOPOIESIS; HUMAN; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LYMPHOCYTE PROLIFERATION; MALIGNANT MESOTHELIOMA; MELANOMA; MELANOMA B16; MOUSE MODEL; MULTIPLE MYELOMA; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL; REHABILITATION; REVIEW; SINGLE DRUG DOSE; SUPPRESSOR CELL; TH17 CELL; THERAPY; TREATMENT DURATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ADAPTIVE IMMUNITY; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84890111958     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.67     Document Type: Review

References (140)

1. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059.
2. Mackay IR, Goodyear MD, Riglar C, Penschow J. Effect on natural killer and antibodydependent cellular cytotoxicity of adjuvant cytotoxic chemotherapy including melphalan in breast cancer. Cancer Immunol Immunother 1983; 16: 98-100.
3. Braun DP, Harris JE. Effect of chemotherapy on NK function in the peripheral blood of cancer patients. Cancer Immunol Immunother 1986; 21: 240-245.
4. Brenner BG, Margolese RG. The relationship of chemotherapeutic and endocrine intervention on natural killer cell activity in human breast cancer. Cancer 1991; 68: 482-488.
5. Sewell HF, Halbert CF, Robins RA, Galvin A, Chan S, Blamey RW. Chemotherapyinduced differential changes in lymphocyte subsets and natural-killer-cell function in patients with advanced breast cancer. Int J Cancer 1993; 55: 735-738.
6. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T-cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56: 641-648.
7. Liu P, Jaffar J, Hellstrom I, Hellstrom KE. Administration of cyclophosphamide changes the immune profile of tumor-bearing mice. J Immunother 2010; 33: 53-59.
8. Doloff JC, Waxman DJ. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Cancer Res 2012; 72: 1103-1115.
9. Khallouf H, Marten A, Serba S, Teichgraber V, Buchler MW, Jager D et al. 5-Fluorouracil and interferon-Alpha immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I. J Immunother 2012; 35: 245-253.
10. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci 2008; 13: 453-461.
11. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000; 164: 6166-6173.
12. Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med 2011; 9: 216.
13. Bryniarski K, Szczepanik M, Ptak M, Zemelka M, Ptak W. Influence of cyclophosphamide and its metabolic products on the activity of peritoneal macrophages in mice. Pharmacol Rep 2009; 61: 550-557.
14. Buhtoiarov IN, Sondel PM, Wigginton JM, Buhtoiarova TN, Yanke EM, Mahvi DA et al. Anti-Tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-Associated macrophages. Immunology 2011; 132: 226-239.
15. Potapov SL, Korman DB, Shamaev VI, Ershova RB, Makarov OV. Sensitivity of clonogenic cells of human ovarian ascitic cancer to antitumor drugs. Arch Geschwulstforsch 1988; 58: 99-104.
16. Park S, Kang S, Chen X, Kim EJ, Kim J, Kim N et al. Tumor suppression via paclitaxelloaded drug carriers that target inflammation marker upregulated in tumor vasculature and macrophages. Biomaterials 2013; 34: 598-605.
17. Javeed A, Ashraf M, Riaz A, Ghafoor A, Afzal S, Mukhtar MM. Paclitaxel and immune system. Eur J Pharm Sci 2009; 38: 283-290.
18. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011; 1: 54-67.
19. Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev 2011; 25: 2465-2479.
20. Nakahara T, Uchi H, Lesokhin AM, Avogadri F, Rizzuto GA, Hirschhorn-Cymerman D et al. Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood 2010; 115: 4384-4392.
21. Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res 2011; 71: 768-778.
22. Chen J, Huang X, Huang G, Chen Y, Chen L, Song H. Preconditioning chemotherapy with cisplatin enhances the antitumor activity of cytokine-induced killer cells in a murine melanoma model. Cancer Biother Radiopharm 2012; 27: 210-220.
23. Soeda A, Morita-Hoshi Y, Makiyama H, Morizane C, Ueno H, Ikeda M et al. Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. Jpn J Clin Oncol 2009; 39: 797-806.
24. Tanaka H, Matsushima H, Mizumoto N, Takashima A. Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells. Cancer Res 2009; 69: 6978-6986.
25. Shurin GV, Tourkova IL, Kaneno R, Shurin MR. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol 2009; 183: 137-144.
26. Kaneno R, Shurin GV, Tourkova IL, Shurin MR. Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J Transl Med 2009; 7: 58.
27. Tanaka H, Matsushima H, Nishibu A, Clausen BE, Takashima A. Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res 2009; 69: 6987-6994.
28. Wehner R, Bitterlich A, Meyer N, Kloss A, Schakel K, Bachmann M et al. Impact of chemotherapeutic agents on the immunostimulatory properties of human 6-sulfo LacNAc+ (slan) dendritic cells. Int J Cancer 2013; 132: 1351-1359.
29. Buttiglieri S, Galetto A, Forno S, De Andrea M, Matera L. Influence of drug-induced apoptotic death on processing and presentation of tumor antigens by dendritic cells. Int J Cancer 2003; 106: 516-520.
30. Galetto A, Buttiglieri S, Forno S, Moro F, Mussa A, Matera L. Drug- And cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells. Anticancer Drugs 2003; 14: 833-843.
31. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N et al. Caspasedependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202: 1691-1701.
32. Mackall CL, Fleisher TA, Brown MR, Magrath IT, Shad AT, Horowitz ME et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994; 84: 2221-2228.
33. Proietti E, Moschella F, Capone I, Belardelli F. Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy. Mol Oncol 2012; 6: 1-14.
34. Wijayahadi N, Haron MR, Stanslas J, Yusuf Z. Changes in cellular immunity during chemotherapy for primary breast cancer with anthracycline regimens. J Chemother 2007; 19: 716-723.
35. Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: Implications for combination chemo-immunotherapy. Cancer Res 2002; 62: 2353-2358.
36. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11: 6713-6721.
37. Shebzukhov YV, Koroleva EP, Khlgatian SV, Lagarkova MA, Meshcheryakov AA, Lichinitser MR et al. Humoral immune response to thymidylate synthase in colon cancer patients after 5-FU chemotherapy. Immunol Lett 2005; 100: 88-93.
38. Otterness IG, Chang YH. Comparative study of cyclophosphamide, 6-mercaptopurine, azathiopurine and methotrexate. Relative effects on the humoral and the cellular immune response in the mouse. Clin Exp Immunol 1976; 26: 346-354.
39. Smith SR, Terminelli C, Kipilman CT, Smith Y. Comparative effects of azathioprine, cyclophosphamide and frentizole on cellular immunity in mice. J Immunopharmacol 1981; 3: 133-170.
40. Berd D, Maguire HC Jr, Mastrangelo MJ. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res 1984; 44: 5439-5443.
41. Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 2007; 13: 644-653.
42. Proietti E, Greco G, Garrone B, Baccarini S, Mauri C, Venditti M et al. Importance of cyclophosphamide-induced bystander effect on T-cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest 1998; 101: 429-441.
43. Moschella F, Valentini M, Arico E, Macchia I, Sestili P, D'Urso MT et al. Unraveling cancer chemoimmunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide. Cancer Res 2011; 71: 3528-3539.
44. Brzostek-Racine S, Gordon C, Van Scoy S, Reich NC. The DNA damage response induces IFN. J Immunol 2011; 187: 5336-5345.
45. Li Q, Teitz-Tennenbaum S, Donald EJ, Li M, Chang AE. In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy. J Immunol 2009; 183: 3195-3203.
46. Montero E, Valdes M, Avellanet J, Lopez A, Perez R, Lage A. Chemotherapy induced transient B-cell depletion boosts antibody-forming cells expansion driven by an epidermal growth factor-based cancer vaccine. Vaccine 2009; 27: 2230-2239.
47. Kim JE, Jang MJ, Lee JI, Chung YH, Jeong JH, Hung CF et al. Cancer cells containing nanoscale chemotherapeutic drugs generate antiovarian cancer-specific CD4+ T-cells in peritoneal space. J Immunother 2012; 35: 1-13.
48. Chang CL, Hsu YT, Wu CC, Lai YZ, Wang C, Yang YC et al. Dose-dense chemotherapy improves mechanisms of antitumor immune response. Cancer Res 2013; 73: 119-127.
49. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A et al. 5-Fluorouracil selectively kills tumor-Associated myeloid-derived suppressor cells resulting in enhanced T-cell-dependent antitumor immunity. Cancer Res 2010; 70: 3052-3061.
50. Predina JD, Judy B, Aliperti LA, Fridlender ZG, Blouin A, Kapoor V et al. Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models. Cancer Gene Ther 2011; 18: 871-883.
51. Tsuchikawa T, Md MM, Yamamura Y, Shichinohe T, Hirano S, Kondo S. The immunological impact of neoadjuvant chemotherapy on the tumor microenvironment of esophageal squamous cell carcinoma. Ann Surg Oncol 2012; 19: 1713-1719.
52. Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 2011; 71: 4809-4820.
53. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318-1321.
54. Vierboom MP, Bos GM, Ooms M, Offringa R, Melief CJ. Cyclophosphamide enhances anti-Tumor effect of wild-Type p53-specific CTL. Int J Cancer 2000; 87: 253-260.
55. Schiavoni G, Mattei F, Di Pucchio T, Santini SM, Bracci L, Belardelli F et al. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: Implications for strategies of chemoimmunotherapy of cancer. Blood 2000; 95: 2024-2030.
56. Ding ZC, Blazar BR, Mellor AL, Munn DH, Zhou G. Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype. Blood 2010; 115: 2397-2406.
57. Boissonnas A, Licata F, Poupel L, Jacquelin S, Fetler L, Krumeich S et al. CD8+ tumorinfiltrating T-cells are trapped in the tumor-dendritic cell network. Neoplasia 2013; 15: 85-94.
58. Kim YH, Choi BK, Oh HS, Kang WJ, Mittler RS, Kwon BS. Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy. Mol Cancer Ther 2009; 8: 469-478.
59. Nistico P, Capone I, Palermo B, Del Bello D, Ferraresi V, Moschella F et al. Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int J Cancer 2009; 124: 130-139.
60. Palermo B, Del Bello D, Sottini A, Serana F, Ghidini C, Gualtieri N et al. Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-Aspecific, tumor-reactive CTL in melanoma patients. Cancer Res 2010; 70: 7084-7092.
61. Zhang L, Dermawan K, Jin M, Liu R, Zheng H, Xu L et al. Differential impairment of regulatory T-cells rather than effector T-cells by paclitaxel-based chemotherapy. Clin Immunol 2008; 129: 219-229.
62. Matar P, Rozados VR, Gervasoni SI, Scharovsky GO. Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother 2002; 50: 588-596.
63. Ghoreschi K, Laurence A, Yang XP, Hirahara K, O'Shea JJ. T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends Immunol 2011; 32: 395-401.
64. Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-1& family members. Immunity 2011; 34: 149-162.
65. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009; 114: 357-359.
66. Bruchard M, Mignot G, Derangere V, Chalmin F, Chevriaux A, Vegran F et al. Chemotherapy-Triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 2013; 19: 57-64.
67. Viaud S, Flament C, Zoubir M, Pautier P, LeCesne A, Ribrag V et al. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res 2011; 71: 661-665.
68. Poschke I, Mougiakakos D, Kiessling R. Camouflage and sabotage: Tumor escape from the immune system. Cancer Immunol Immunother 2011; 60: 1161-1171.
69. Mantovani A, Sica A, Allavena P, Garlanda C, Locati M. Tumor-Associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol 2009; 70: 325-330.
70. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999; 59: 3128-3133.
71. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP et al. Synergism of cytotoxic T lymphocyte-Associated antigen 4 blockade and depletion of CD25(+) regulatory T-cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194: 823-832.
72. Najjar YG, Finke JH. Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol 2013; 3: 49.
73. Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, Benninger K, Khan M, Kuppusamy P et al. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res 2011; 71: 5101-5110.
74. Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D, Jansen BJ, Nierkens S et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest 2011; 121: 3100-3108.
75. Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N et al. CD4+CD25+ regulatory T-cells inhibit natural killer cell functions in a transforming growth factor-betadependent manner. J Exp Med 2005; 202: 1075-1085.
76. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105: 2862-2868.
77. Guerriero JL, Ditsworth D, Catanzaro JM, Sabino G, Furie MB, Kew RR et al. DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity. J Immunol 2011; 186: 3517-3526.
78. Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: Immunological effects and clinical outcome. Cancer Immunol Immunother 2012; 61: 353-362.
79. Banissi C, Ghiringhelli F, Chen L, Carpentier AF. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother 2009; 58: 1627-1634.
80. Brooks-Kaiser JC, Bourque LA, Hoskin DW. Heterogeneity of splenic natural suppressor cells induced in mice by treatment with cyclophosphamide. Immunopharmacology 1993; 25: 117-129.
81. Nikcevich DA, Duffie GP, Young MR, Ellis NK, Kaufman GE, Wepsic HT. Stimulation of suppressor cells in the bone marrow and spleens of high dose cyclophosphamide-Treated C57Bl/6 mice. Cell Immunol 1987; 109: 349-359.
82. Segre M, Tomei E, Segre D. Cyclophosphamide-induced suppressor cells in mice: Suppression of the antibody response in vitro and characterization of the effector cells. Cell Immunol 1985; 91: 443-454.
83. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin- cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58: 49-59.
84. Salem ML, Al-Khami AA, El-Naggar SA, Diaz-Montero CM, Chen Y, Cole DJ. Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells. J Immunol 2010; 184: 1737-1747.
85. Sevko A, Sade-Feldman M, Kanterman J, Michels T, Falk CS, Umansky L et al. Cyclophosphamide Promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J Invest Dermatol 2012; 133: 1610-1619.
86. Pelaez B, Campillo JA, Lopez-Asenjo JA, Subiza JL. Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxidedependent mechanism. J Immunol 2001; 166: 6608-6615.
87. Tongu M, Harashima N, Monma H, Inao T, Yamada T, Kawauchi H et al. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-Tumor T-cell immunity in vivo. Cancer Immunol Immunother 2012; 62: 383-391.
88. Zhu Y, Liu N, Xiong SD, Zheng YJ, Chu YW. CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is independent of toll-like receptor 4. Scand J Immunol 2011; 73: 301-308.
89. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: Suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010; 16: 4583-4594.
90. Apetoh L, Vegran F, Ladoire S, Ghiringhelli F. Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies. Curr Mol Med 2011; 11: 365-372.
91. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12: 253-268.
92. Sim SH, Ahn YO, Yoon J, Kim TM, Lee SH, Kim DW et al. Influence of chemotherapy on nitric oxide synthase, indole-Amine-2,3-dioxygenase and CD124 expression in granulocytes and monocytes of non-small cell lung cancer. Cancer Sci 2012; 103: 155-160.
93. Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C, Kroemer G. Prognostic and predictive impact of intra- And peritumoral immune infiltrates. Cancer Res 2011; 71: 5601-5605.
94. Lake RA, Robinson BW. Immunotherapy and chemotherapy-A practical partnership. Nat Rev Cancer 2005; 5: 397-405.
95. Cassinelli G, Supino R, Perego P, Polizzi D, Lanzi C, Pratesi G et al. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int J Cancer 2001; 92: 738-747.
96. Salomons GS, Smets LA, Verwijs-Janssen M, Hart AA, Haarman EG, Kaspers GJ et al. Bcl-2 family members in childhood acute lymphoblastic leukemia: Relationships with features at presentation, in vitro and in vivo drug response and long-Term clinical outcome. Leukemia 1999; 13: 1574-1580.
97. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret al.ly: Immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11: 215-233.
98. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29: 482-491.
99. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013; 38: 729-741.
100. Correale P, Cusi MG, Del Vecchio MT, Aquino A, Prete SP, Tsang KY et al. Dendritic cellmediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. J Immunol 2005; 175: 820-828.
101. Kim TG, Kim CH, Park JS, Park SD, Kim CK, Chung DS et al. Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. Clin Vaccine Immunol 2010; 17: 143-153.
102. Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L et al. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 2009; 14: 364-375.
103. Vitale I, Galluzzi L, Castedo M, Kroemer G. Mitotic catastrophe: A mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 2011; 12: 385-392.
104. Apel A, Zentgraf H, Buchler MW, Herr I. Autophagy-A double-edged sword in oncology. Int J Cancer 2009; 125: 991-995.
105. Yu L, Alva A, Su H, Dutt P, Freundt E, Welsh S et al. Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science 2004; 304: 1500-1502.
106. Agarwala SS, Case S. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: A review. Oncologist 2010; 15: 236-245.
107. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007; 117: 326-336.
108. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P et al. Autophagydependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334: 1573-1577.
109. Bergmann-Leitner ES, Abrams SI. Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes. Cancer Immunol Immunother 2001; 50: 445-455.
110. Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, Antonia S et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 2010; 120: 1111-1124.
111. van der Most RG, Currie AJ, Cleaver AL, Salmons J, Nowak AK, Mahendran S et al. Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T-cellmediated immune attack resulting in suppression of tumor growth. PLoS One 2009; 4: E6982.
112. Ullrich E, Bonmort M, Mignot G, Jacobs B, Bosisio D, Sozzani S et al. Trans-presentation of IL-15 dictates IFN-producing killer dendritic cells effector functions. J Immunol 2008; 180: 7887-7897.
113. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005; 436: 1186-1190.
114. Fine JH, Chen P, Mesci A, Allan DS, Gasser S, Raulet DH et al. Chemotherapy-induced genotoxic stress promotes sensitivity to natural killer cell cytotoxicity by enabling missingself recognition. Cancer Res 2010; 70: 7102-7113.
115. Liu WM, Fowler DW, Smith P, Dalgleish AG. Pre-Treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 2010; 102: 115-123.
116. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-Tolerizing host tumor-specific CD8 T-cells. J Immunol 2003; 170: 4905-4913.
117. Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V et al. ATMATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 2009; 113: 3503-3511.
118. Botnick LE, Hannon EC, Vigneulle R, Hellman S. Differential effects of cytotoxic agents on hematopoietic progenitors. Cancer Res 1981; 41: 2338-2342.
119. Ferrari S, Rovati B, Porta C, Alessandrino PE, Bertolini A, Collova E et al. Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or highdose chemotherapy plus granulocyte-colony stimulating factor. Cancer Immunol Immunother 2003; 52: 359-366.
120. Radojcic V, Bezak KB, Skarica M, Pletneva MA, Yoshimura K, Schulick RD et al. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T-cell elimination. Cancer Immunol Immunother 2010; 59: 137-148.
121. Salem ML, El-Naggar SA, Cole DJ. Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T-cells in vivo. Cell Immunol 2010; 261: 134-143.
122. Sefc L, Psenak O, Sykora V, Sulc K, Necas E. Response of hematopoiesis to cyclophosphamide follows highly specific patterns in bone marrow and spleen. J Hematother Stem Cell Res 2003; 12: 47-61.
123. Salem ML, Kadima AN, El-Naggar SA, Rubinstein MP, Chen Y, Gillanders WE et al. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: Creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother 2007; 30: 40-53.
124. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies. Cancer Res 2000; 60: 1388-1393.
125. Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: Chemotherapeutics as antiangiogenics. J Clin Oncol 2001; 19: 1195-1206.
126. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003; 63: 4342-4346.
127. Loeffler M, Kruger JA, Reisfeld RA. Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. Cancer Res 2005; 65: 5027-5030.
128. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
129. Robert C, Thomas L, Bondarenko I, O'Day S, DJM, Garbe C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
130. Zielinski C, Knapp S, Mascaux C, Hirsch F. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Ann Oncol 2013; 24: 1170-1179.
131. Lorenzi S, Mattei F, Sistigu A, Bracci L, Spadaro F, Sanchez M et al. Type I IFNs control antigen retention and survival of CD8{alpha}+ dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. J Immunol 2011; 186: 5142-5150.
132. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12: 237-251.
133. Farsaci B, Higgins JP, Hodge JW. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer 2012; 130: 1948-1959.
134. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15: 2148-2157.
135. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H et al. Imatinib potentiates antitumor T-cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011; 17: 1094-1100.
136. Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-Activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 2005; 65: 9525-9535.
137. Seeger JM, Schmidt P, Brinkmann K, Hombach AA, Coutelle O, Zigrino P et al. The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack. Cancer Res 2010; 70: 1825-1834.
138. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70: 5213-5219.
139. Correale P, Botta C, Cusi MG, Del Vecchio MT, De Santi MM, Gori Savellini G et al. Cetuximab +/- chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. Int J Cancer 2012; 130: 1577-1589.
140. Kim PS, Armstrong TD, Song H, Wolpoe ME, Weiss V, Manning EA et al. Antibody association with HER-2/neu-Targeted vaccine enhances CD8 T-cell responses in mice through Fc-mediated activation of DCs. J Clin Invest 2008; 118: 1700-1711.